Xiaolin Dong

Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in <scp>SUSTAIN China</scp> : A 30‐week, double‐blind, phase 3a, randomized trial

Linong Ji, Xiaolin Dong, Yiming Li et al. · Diabetes Obesity and Metabolism · 2020 · 103 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study

Dalong Zhu, Shenglian Gan, Yu Liu et al. · The Lancet Diabetes & Endocrinology · 2018 · 102 citations

Medicine, Pharmacology, Pharmacotherapy +10

Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Dalong Zhu, Jianhua Ma, Jiao’e Zeng et al. · Nature Medicine · 2022 · 94 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

Wenying Yang, Dalong Zhu, Shenglian Gan et al. · Nature Medicine · 2022 · 76 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficiency of anthropometric indicators of obesity for identifying cardiovascular risk factors in a Chinese population

Xiaolin Dong, Yang Liu, Jie Yang et al. · Postgraduate Medical Journal · 2011 · 53 citations

Public Health, Health Sciences, Epidemiology +16